ES2855998T3 - Etiqueta transglutamina para bioconjugación específica de sitio eficiente - Google Patents
Etiqueta transglutamina para bioconjugación específica de sitio eficiente Download PDFInfo
- Publication number
- ES2855998T3 ES2855998T3 ES16753248T ES16753248T ES2855998T3 ES 2855998 T3 ES2855998 T3 ES 2855998T3 ES 16753248 T ES16753248 T ES 16753248T ES 16753248 T ES16753248 T ES 16753248T ES 2855998 T3 ES2855998 T3 ES 2855998T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- tyfqayg
- amino acid
- antibody
- donor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15180278 | 2015-08-07 | ||
| PCT/EP2016/001344 WO2017025179A1 (en) | 2015-08-07 | 2016-08-04 | A transglutamine tag for efficient site-specific bioconjugation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2855998T3 true ES2855998T3 (es) | 2021-09-27 |
Family
ID=53785570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16753248T Active ES2855998T3 (es) | 2015-08-07 | 2016-08-04 | Etiqueta transglutamina para bioconjugación específica de sitio eficiente |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11130818B2 (https=) |
| EP (1) | EP3331904B1 (https=) |
| JP (1) | JP7008014B2 (https=) |
| CN (1) | CN107922479A (https=) |
| AU (1) | AU2016306907A1 (https=) |
| CA (1) | CA2994741A1 (https=) |
| ES (1) | ES2855998T3 (https=) |
| IL (1) | IL256810B (https=) |
| WO (1) | WO2017025179A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3419670A2 (en) * | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| EP3272864A1 (en) * | 2016-07-20 | 2018-01-24 | Paul Scherrer Institut | Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation |
| NZ762376A (en) | 2017-09-19 | 2022-08-26 | Scherrer Inst Paul | Transglutaminase conjugation method and linker |
| KR102861586B1 (ko) * | 2018-11-30 | 2025-09-17 | 브리스톨-마이어스 스큅 컴퍼니 | 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도 |
| CA3128571A1 (en) | 2019-03-19 | 2020-09-24 | Paul Scherrer Institut | Transglutaminase conjugation method with a glycine based linker |
| EP3865155B1 (en) | 2020-02-13 | 2022-11-30 | Orano Med | Process for site-specific modification of an antibody |
| KR20230069211A (ko) | 2020-09-18 | 2023-05-18 | 아라리스 바이오테크 아게 | 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법 |
| KR20230096052A (ko) | 2020-10-25 | 2023-06-29 | 아라리스 바이오테크 아게 | 항체-링커 접합체를 생성하기 위한 수단 및 방법 |
| WO2023072934A1 (en) | 2021-10-25 | 2023-05-04 | Araris Biotech Ag | Methods for producing antibody-linker conjugates |
| JP2025506650A (ja) * | 2022-02-17 | 2025-03-13 | レボロ バイオセラピューティクス リミテッド | シャペロニン６０．１由来のペプチドを作製する方法 |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| WO2024211135A2 (en) * | 2023-04-07 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Characterization of crosslinking sites in antibody-drug conjugates |
| AU2024318241A1 (en) * | 2023-07-31 | 2026-02-19 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate having high drug load and use thereof |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
| WO2026013234A1 (en) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Triple-payload antibody-drug conjugates (adcs) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| CA2527665A1 (en) * | 2003-05-30 | 2004-12-16 | Centocor, Inc. | Formation of novel erythropoietin conjugates using transglutaminase |
| ES2642214T3 (es) * | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
| US11376333B2 (en) | 2013-12-23 | 2022-07-05 | Covalab | mTG substrates for covalent conjugation of compounds |
| UA124622C2 (uk) * | 2015-12-18 | 2021-10-20 | ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. | Кон'юговані імуноглобуліни з c-кінцевим лізином |
-
2016
- 2016-08-04 ES ES16753248T patent/ES2855998T3/es active Active
- 2016-08-04 CN CN201680046587.7A patent/CN107922479A/zh active Pending
- 2016-08-04 EP EP16753248.0A patent/EP3331904B1/en active Active
- 2016-08-04 AU AU2016306907A patent/AU2016306907A1/en not_active Abandoned
- 2016-08-04 US US15/750,725 patent/US11130818B2/en not_active Expired - Fee Related
- 2016-08-04 WO PCT/EP2016/001344 patent/WO2017025179A1/en not_active Ceased
- 2016-08-04 CA CA2994741A patent/CA2994741A1/en not_active Abandoned
- 2016-08-04 JP JP2018506297A patent/JP7008014B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-09 IL IL256810A patent/IL256810B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11130818B2 (en) | 2021-09-28 |
| WO2017025179A1 (en) | 2017-02-16 |
| CN107922479A (zh) | 2018-04-17 |
| WO2017025179A8 (en) | 2018-04-19 |
| CA2994741A1 (en) | 2017-02-16 |
| AU2016306907A1 (en) | 2018-03-29 |
| EP3331904B1 (en) | 2020-12-23 |
| AU2016306907A9 (en) | 2019-07-25 |
| EP3331904A1 (en) | 2018-06-13 |
| US20190194344A1 (en) | 2019-06-27 |
| IL256810A (en) | 2018-03-29 |
| JP2018529321A (ja) | 2018-10-11 |
| JP7008014B2 (ja) | 2022-02-10 |
| IL256810B (en) | 2021-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2855998T3 (es) | Etiqueta transglutamina para bioconjugación específica de sitio eficiente | |
| JP7360377B2 (ja) | アントラサイクリン誘導体を含む、結合タンパク質薬物複合体（Ｂｉｎｄｉｎｇ ｐｒｏｔｅｉｎ ｄｒｕｇ ｃｏｎｊｕｇａｔｅｓ） | |
| JP6619743B2 (ja) | 抗体−薬物複合体及び免疫毒素 | |
| AU2017279352B2 (en) | Lysine conjugated immunoglobulins | |
| US20220111064A1 (en) | Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof | |
| CN102665768B (zh) | 肽清除剂 | |
| ES2876151T3 (es) | Anticuerpos anti-c-met y sus conjugados fármaco-anticuerpo para una inhibición tumoral eficiente | |
| AU4166701A (en) | Caspase activated prodrugs therapy | |
| CN114828895A (zh) | 制备基于艾日布林的抗体-药物缀合物的方法 | |
| US20180028682A1 (en) | Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation | |
| US11723984B2 (en) | Method for conjugating antibody and physiologically active substance | |
| CN118922447A (zh) | 靶向叶酸受体α的抗体-药物缀合物及使用方法 | |
| HK40068270A (en) | Methods of using a bispecific antigen-binding construct targeting her2 for the treatment of biliary tract cancers | |
| EA040604B1 (ru) | Конъюгаты, связывающие белок-лекарственное средство, содержащие производные антрациклина |